Keros Therapeutics, Inc. (NASDAQ:KROS) Stock Drop

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, experienced a significant decline in stock value after announcing a voluntary pause in dosing for certain arms of its Phase 2 TROPOS Trial.

Reasons for Pause

The pause was implemented following a safety review that identified unexpected instances of pericardial effusion—excess fluid accumulation around the heart—among trial participants.

About TROPOS Trial

The TROPOS trial, which is fully enrolled, is assessing the safety and efficacy of cibotercept (KER-012) in combination with standard therapy for patients suffering from pulmonary arterial hypertension (PAH). Due to the adverse events, dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms has been halted. However, dosing at the 1.5 mg/kg level continues, following a risk-benefit assessment by the independent Data Monitoring Committee (DMC) and a select group of unblinded individuals at Keros.

Commitment to Safety

Dr. Jasbir S. Seehra, Chair and CEO of Keros, reiterated the company's dedication to patient safety, stating, "We are working diligently to gain a better understanding of these unanticipated findings." Keros is collaborating with trial investigators, the U.S. Food and Drug Administration (FDA), and other regulatory bodies to address the concerns promptly.

Ongoing Data Collection

Despite the halt in dosing for higher treatment arms, Keros will continue gathering safety and efficacy data for all trial groups. The company has updated trial investigators and the FDA about this dosing suspension and is notifying other relevant regulatory entities. Keros expects to present topline data from all treatment arms of the TROPOS trial in Q2 2025 and will share further updates as they become available.

> This article was generated with the support of AI and reviewed by an editor. For more information, see our T&C.